Jiawei Zeng

Jiawei Zeng

Auto-generated profile, based on publicly available information

Jiawei Zeng

The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2014 in Apoptosis
Verified
Journal Article
Closed access
PDF file
JZJia-Wei Zeng
Jia-Wei Zeng
XZXue-Lin Zeng
Xue-Lin Zeng
FLFei-Ya Li
Fei-Ya Li
MMMing-Ming Ma
Ming-Ming Ma
FYFeng Yuan
Feng Yuan
YGYong-Yuan Guan
Yong-Yuan Guan

1 August 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
JZJiawei Zeng
Jiawei Zeng
LZLidan Zhang
Lidan Zhang
MGMin Gao
Min Gao
JWJingjing Wu
Jingjing Wu
HWHaiyan Wu
Haiyan Wu
WTWen Tang
Wen Tang
The successful use of tigecycline in a 12-month old liver transplant recipient with extensively drug-resistant Acinetobacter baumannii bacteremia is presented. Tigecycline serum concentrations were monitored to help improve antibiotic efficacy and minimize side effects. A literature review identified 11 additional pediatric cases of A. baumannii infection treated with tigecycline since 2011. Tigecycline treatment should be considered in children with extensively drug-resistant bacterial infections.

10 June 2014 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
JZJia‐Wei Zeng
Jia‐Wei Zeng
XWXiao‐Guang Wang
Xiao‐Guang Wang
MMMing‐Ming Ma
Ming‐Ming Ma
XLXiao‐Fei Lv
Xiao‐Fei Lv
JLJie Liu
Jie Liu
YGYong-Yuan Guan
Yong-Yuan Guan

30 December 2020 in Journal of Applied Ichthyology
Verified
Journal Article
Open access
PDF file
SLShaoliang LYU
Shaoliang LYU
KLKun Lin
Kun Lin
JZJiawei Zeng
Jiawei Zeng
YLYuxi Liu
Yuxi Liu
ZCZhijie Chen
Zhijie Chen
XWXuefeng Wang
Xuefeng Wang
The purpose of this study was to develop a novel method for the external attachment of ultrasonic transmitters on hard fin‐spines fish (Sparidae). Acanthopagrus latus, one of the main stocking Sparidae fishes in the northern South China Sea, was employed to conduct the 40‐day tank experiment by using dummy ultrasonic transmitters. The experiment consisted of 3 treatment groups, i.e., drilling on dorsal fin‐spine (DD) group, drilling on anal fin‐spine (DA) group, and control (C) group, with each group having 3 replicates and 30 fish per replicate. The feasibilities of DD and DA for the external attachment of ultrasonic transmitters were tested and evaluated using parameters: the specific growth rate, survival rate, and tag retention rate of each group. And the tagging procedures for the external attachment of hard fin‐spines fish were also proposed. The results showed that there were no significant differences in the specific growth rate of fish between groups. Both the survival rates of DD group (96.67%) and DA group (94.44%) were less (but not significant) than C group (97.78%), while the tag retention rate of DA group (100%) was higher (but not significant) than DD group (98.89%). These results demonstrate that drilling on dorsal or anal fin‐spines is feasible as an external attachment method of ultrasonic transmitters on Sparidae fishes. In addition, considering the friction between the tagged transmitters and rocks at the bottom of natural waters, which possibly affect the fish behaviors such as swimming, feeding, etc., or lead to tag loss, so drilling on the dorsal fin‐spine is preferred for rocky‐bottom Sparidae fishes like A. latus as small as 14 cm body length.

6 February 2021 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
YLYujian M.S. Liang
Yujian M.S. Liang
ZWZhaoyi M.S Wu
Zhaoyi M.S Wu
LZLiyan Zhao
Liyan Zhao
JWJingjing B.S Wu
Jingjing B.S Wu
XCXiao Chen
Xiao Chen
JZJiawei M.D Zeng
Jiawei M.D Zeng
Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease. Initial therapy is based on etoposide, dexamethasone, and cyclosporine (CSA). The pharmacokinetics (PKs) of CSA and other drugs are sometimes altered in patients with HLH complicated by diabetes insipidus (DI) but the precise mechanisms remain unknown. Methods: In this study, the authors present a case of a 4-year-old boy with HLH complicated by DI. CSA concentrations were determined by enzyme multiplied immunoassay technique; noncompartmental PK analysis of the plasma concentration–time data was performed using PKSolver; and linear regression analysis was performed to determine linearity of relationship between urine output and C0 levels of CSA. Results: Although C0 values of CSA were lower than the target levels, the patient was successfully treated and a good clinical outcome was achieved. Linear regression analysis showed a strong negative correlation between urine output and the serum trough concentration (C0) of CSA, pharmacokinetic analysis showed the main PK parameters of CSA as follows: C0, 50.2 mcg/L; peak concentration (Cmax), 723.4 mcg/L; area under the curve0–24, 7478.2 mcg·h/L; clearance, 0.77 L/h/kg, elimination half-life, 5.3 hours, and volume of distribution, 6.0 L/kg. Conclusions: To the best of the authors' knowledge, this is the first report of the CSA PK profile in a patient with HLH complicated by DI. The authors suppose that a large fluid output and input leads to extensive CSA distribution. These results suggest that the monitoring of the Cmax and area under the curve of CSA might be more clinically and pharmacokinetically significant than that of C0 in patients with HLH complicated by DI. This case highlights the importance of therapeutic drug monitoring and demonstrates PK parameters of CSA in a pediatric patient with HLH complicated by DI.

6 March 2024 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
GYGang Yuan
Gang Yuan
YCYili Chen
Yili Chen
LLLi Li
Li Li
XWXin Wang
Xin Wang
GWGang Wei
Gang Wei
MCMinhu Chen
Minhu Chen
Background. Tenapanor is a locally acting selective sodium-hydrogen exchanger 3 inhibitor with the potential to treat sodium/phosphorus and fluid overload in various cardiac-renal diseases, which has been approved for constipation-predominant irritable bowel syndrome in the US. The pharmacokinetics (PK) of tenapanor and its metabolite tenapanor-M1 (AZ13792925), as well as the safety and tolerability of tenapanor, were investigated in healthy Chinese and Caucasian subjects. Methods. This randomized, open-label, single-center, placebo-controlled phase 1 study (https://www.chinadrugtrials.org.cn; CTR20201783) enrolled Chinese and Caucasian healthy volunteers into 4 parallel cohorts (3 cohorts for Chinese subjects, 1 cohort for Caucasian subjects). In each cohort, 15 subjects were expected to be included and received oral tenapanor (10 or 30 mg as single dose, or 50 mg as a single dose followed by a twice-daily repeated dose from Day 5 to 11, with a single dose in the morning on Day 11) or placebo in a 4 : 1 ratio. Results. 59 healthy volunteers received tenapanor 10 mg (n = 12 Chinese), 30 mg (n = 12 Chinese), or 50 mg (n = 12 (Chinese), n = 11 (Caucasian)) or placebo (n = 12, 3 per cohort). After single and twice-daily repeated doses, tenapanor plasma concentrations were all below the limit of quantitation; tenapanor-M1 appeared slowly in plasma. In single-ascending dose evaluation (10 to 50 mg) of Chinese subjects, the mean Cmax, AUC0-t, and AUC0-∞ of tenapanor-M1 increased with increasing dose level, and AUC0-t increased approximately dose proportionally. The Cmax accumulation ratio was 1.55 to 6.92 after 50 mg repeated dose in Chinese and Caucasian subjects. Exposure to tenapanor-M1 was generally similar between the Chinese and Caucasian subjects. Tenapanor was generally well-tolerated and the safety profile was similar between the Chinese and Caucasian participants receiving tenapanor 50 mg, as measured by vital signs, physical and laboratory examination, 12-lead ECG, and adverse events. No serious adverse event or adverse event leading to withdrawal occurred. Conclusion. Tenapanor was well-tolerated, with similar PK and safety profiles between Chinese and Caucasian subjects. This trial is registered with CTR20201783.